AstraZeneca says Dato-DXd ‘continued to demonstrate encouraging responses’

Updated results from the TROPION-PanTumor01 Phase I trial showed datopotamab deruxtecan, or "Dato-DXd," continued to "demonstrate encouraging responses" in patients with heavily pretreated metastatic triple-negative breast cancer, or TNBC, and disease progression following standard treatment. Results were presented today at the 2022 San Antonio Breast Cancer Symposium, or SABCS, announced AstraZeneca (AZN) and Daiichi Sankyo (DSNKY), who are jointly developing datopotamab deruxtecan. In the TNBC cohort of TROPION-PanTumor01, datopotamab deruxtecan demonstrated an objective response rate, or ORR, of 32%, including one complete response, or CR, 13 partial responses, or PRs, and 18 cases of stable disease as assessed by blinded independent central review. In a subgroup of 27 patients who had not been treated with topoisomerase I inhibitor-based ADCs, the ORR was 44%, including one CR, 11 PRs and 10 cases of SD. The median duration of response, or DoR, was 16.8 months across patient groups. In the overall cohort, datopotamab deruxtecan demonstrated median progression-free survival, or PFS, of 4.4 months and median overall survival, or OS, of 13.5 months. In the subgroup of patients who had not been treated with a topoisomerase I inhibitor, median PFS and OS were 7.3 months and 14.3 months, respectively. The disease control rate was consistent across the overall cohort and previously untreated subgroup at 80% and 81%, respectively.